The Texas Heart Institute’s Drs. Salim Virani and Matthew Segar look back at the history of Sglt2 inhibitors, which have roots in a fascinating FDA initiative focused on cardiovascular outcomes in diabetes medications. They explore the serendipitous beginnings of these groundbreaking medicines and their significant impact on cardiovascular health.

Where to listen: https://www.texasheart.org/office-of-education/podcasts/

Read the full THI Journal Article: https://meridian.allenpress.com/thij/article/51/1/e238375/499792/Cardiovascular-Disease-Management-With-Sodium

Allan Zhang, Ramsey Kalil, Alexander Marzec, Stephanie A. Coulter, Salim Virani, Kershaw V. Patel, Matthew W. Segar; Cardiovascular Disease Management With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Cardiology Primer. Tex Heart Inst J 1 January 2024; 51 (1): e238375. doi: https://doi.org/10.14503/THIJ-23-8375

About The Point:
The Texas Heart Institute produces The Point to discuss newly published clinical research and emerging developments and innovations in patient care. Designed to infuse your day with the latest medical knowledge and a dash of banter, faculty and fellows dive into newly published research and its significance to patient care today and in the future.